Listed

Opus Genetics, Inc.: Form 10-K for the period ended Dec 31, 2019

Filed with the SEC on Feb 21, 2020 and accepted by EDGAR at Feb 21, 2020, 16:39 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2019-01-01 to 2019-12-31$3.0mus-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
Research and development12 months2019-01-01 to 2019-12-31$5.5mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2019-01-01 to 2019-12-31−$11.2mus-gaap:OperatingIncomeLoss
Net income12 months2019-01-01 to 2019-12-31−$8.6mus-gaap:NetIncomeLoss
Diluted EPS12 months2019-01-01 to 2019-12-31−$2.18us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2019-01-01 to 2019-12-31−$10.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Current assetsAt period end2019-12-31$12.7mus-gaap:AssetsCurrent
Total assetsAt period end2019-12-31$13.0mus-gaap:Assets
Current liabilitiesAt period end2019-12-31$2.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-12-31$3.0mus-gaap:Liabilities
Shareholders' equityAt period end2019-12-31$10.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001140361-20-003785. Last ingested by Listed: Nov 12, 2026, 19:22 ET. Listed shows no prices and gives no investment advice.